dr. wang on comparative analysis of kte-x19 in higher- versus lower-risk r/r mcl
Published 4 years ago • 37 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
1:29
dr. wang on the impact of kte-x19 on outcomes in higher- versus lower-risk mcl
-
1:31
dr. wang on the efficacy of kte-x19 in low- and high-risk r/r mcl
-
1:20
dr. wang on the safety and efficacy of kte-x19 in r/r mcl
-
0:47
dr. wang on the safety profile of kte-x19 in mcl
-
1:19
dr. wang on unique properties of kte-x19 in relapsed/refractory mcl
-
0:55
dr. wang on the evolution of treatment in mcl
-
1:10
dr. miklos on the safety profile of kte-x19 in mcl
-
1:59
dr. wang on ongoing research in mcl
-
53:53
mantle cell lymphoma case
-
1:07
dr. wang on addition of acalabrutinib to bendamustine/rituximab in mcl
-
2:19
dr. wang on the fda approval of brexucabtagene autoleucel in mcl
-
0:54
dr. wang on updated data with single-agent acalabrutinib in mcl
-
1:11
one-year follow-up of zuma-2: kte-x19 in r/r mcl
-
1:51
dr. wang on research trends in mcl
-
0:51
dr. wang on precision medicine in mcl
-
1:04
dr. wang on the safety profile of brexucabtagene autoleucel in relapsed/refractory mcl
-
1:57
dr. wang on combatting car t-cell therapy resistance in mcl
-
1:19
dr. wang on triplet vorinostat regimen in newly diagnosed mcl
-
1:01
dr. wang on future research with car t-cell therapy in mcl
-
1:08
dr. wang discusses the future of treatment in mcl
-
1:23
dr. miklos on anticipated sequencing challenges with kte-x19 in mcl
-
1:15
dr. wang on the pace of progress in mcl